169 related articles for article (PubMed ID: 31540832)
1. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.
Paffenholz P; Nestler T; Hoier S; Pfister D; Hellmich M; Heidenreich A
Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832
[TBL] [Abstract][Full Text] [Related]
2. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
[TBL] [Abstract][Full Text] [Related]
3. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer.
Li R; Duplisea JJ; Petros FG; González GMN; Tu SM; Karam JA; Huynh TT; Ward JF
Eur Urol Oncol; 2021 Aug; 4(4):651-658. PubMed ID: 31412007
[TBL] [Abstract][Full Text] [Related]
4. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
5. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.
Baessler B; Nestler T; Pinto Dos Santos D; Paffenholz P; Zeuch V; Pfister D; Maintz D; Heidenreich A
Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
Antonelli L; Ardizzone D; Tachibana I; Adra N; Cary C; Hugar L; Sexton WJ; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Cazzaniga W; Nicol D; Gerdtsson A; Tandstad T; Fizazi K; Fankhauser CD;
J Clin Oncol; 2023 Dec; 41(34):5296-5305. PubMed ID: 37656935
[TBL] [Abstract][Full Text] [Related]
7. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
8. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
Nguyen CT; Stephenson AJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
[TBL] [Abstract][Full Text] [Related]
9. Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue.
Nestler T; Kremer L; von Brandenstein M; Wittersheim M; Paffenholz P; Wagener-Ryczek S; Quaas A; Hellmich M; Müller S; Pfister D; Odenthal M; Heidenreich A
Cancer; 2023 Feb; 129(4):634-642. PubMed ID: 36504384
[TBL] [Abstract][Full Text] [Related]
10. Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?
Riggs SB; Burgess EF; Gaston KE; Merwarth CA; Raghavan D
Oncologist; 2014 May; 19(5):498-506. PubMed ID: 24718515
[TBL] [Abstract][Full Text] [Related]
11. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.
Gupta A; Feifer AH; Gotto GT; Kraus D; Motzer R; Bosl GJ; Bajorin D; Feldman DR; Carver B; Sheinfeld J
Urology; 2011 Mar; 77(3):655-9. PubMed ID: 21377010
[TBL] [Abstract][Full Text] [Related]
15. Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.
Pietzak EJ; Assel M; Becerra MF; Tennenbaum D; Feldman DR; Bajorin DF; Motzer RJ; Bosl GJ; Carver BS; Sjoberg DD; Sheinfeld J
Urology; 2018 Aug; 118():114-118. PubMed ID: 29704586
[TBL] [Abstract][Full Text] [Related]
16. The Role of Postchemotherapy Surgery in Germ Cell Tumors.
Chéry L; Dash A
Urol Clin North Am; 2015 Aug; 42(3):331-42. PubMed ID: 26216820
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic Retroperitoneal Lymph Node Dissection as a Safe Procedure for Postchemotherapy Residual Mass in Testicular Cancer.
Faria EF; Neves HS; Dauster B; Machado RD; Magnabosco WJ; Muller RL; Santos AC; Tobias-Machado M
J Laparoendosc Adv Surg Tech A; 2018 Feb; 28(2):168-173. PubMed ID: 29215949
[TBL] [Abstract][Full Text] [Related]
19. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
20. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]